ArticleEuropean stroke journal2026
Sex disparities in case fatality rate after aneurysmal subarachnoid haemorrhage: a prospective longitudinal population-based cohort study.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionWhile increased female susceptibility to intracranial aneurysm development and rupture is well-known, data on sex differences in case fatality rates (CFR) after aneurysmal subarachnoid haemorrhage (aSAH) remain conflicting. We aimed to investigate sex differences in 90-day CFR post-aSAH and identify explanatory factors. PATIENTS AND
methodsThe UK Biobank is a prospective population-based cohort study, including 502,411 participants, with baseline assessments between 2006 and 2010. Participants who developed aSAH during follow-up were identified through linkage with hospitalisation records and national death registries. Primary outcome was 90-day CFR post-aSAH. Kaplan-Meier survival analysis and multivariable Cox proportional hazard regression assessed sex disparities in CFR and potential explanatory factors.
resultsWe included 990 participants with aSAH, 634 (64.0%) females (age 66.0 ± 8.4) and 356 males (36.0%) (65.1 ± 8.6). At 90 days, 214 of 634 females (33.8%) and 98 of 356 males (27.5%) had died (OR 1.34; 95% CI, 1.01-1.78). Survival analysis demonstrated a sex difference in 90-day CFR (log-rank P = .046) with early divergence and consistently lower survival probability in females. After adjusting for age and covariates that varied by sex at baseline and at time of aSAH, hazard ratio (HR) for case fatality in females was 1.15 (95% CI, 0.90-1.49). In sex-specific multivariable models, HRs for case fatality for age were 1.04 (95% CI, 1.02-1.06) in females and 1.04 (95% CI, 1.01-1.07) in males; for anti-hypertensives use 1.76 (95% CI, 1.23-2.51) and 1.98 (95% CI, 1.23-3.17); and for current smoking 1.87 (95% CI, 1.31-2.67) and 1.64 (95% CI, 0.95-2.82). DISCUSSION AND
conclusionFemales had a higher unadjusted 90-day CFR post-aSAH. This sex difference is partially explained by higher age at aSAH and differences in modifiable baseline risk factors such as hypertension and smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.